BRISTOL-MYERS SQUIBB COMPANY vs Pfizer Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BMY and PFE diverge most: on return on equity, BMY reads 41.6% and PFE reads 8.3%; on p/b, BMY reads 5.99 and PFE reads 1.59. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BMY | PFE |
|---|---|---|
| Price | $65.30 | $25.03 |
| Market cap | $133.7B | $143.4B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | -2.9% |
| P/E | 14.3 | 19.1 |
| P/B | 5.99 | 1.59 |
| P/S | 2.72 | 2.27 |
| EV/EBITDA | 47.4 | 31.3 |
| Revenue growth | +3.1% | +2.1% |
| Net margin | 18.9% | 11.8% |
| Return on equity | 41.6% | 8.3% |
| Return on assets | 10.6% | 3.6% |
| FCF yield | 8.6% | 6.6% |
| Dividend yield | 3.8% | 6.9% |
| Debt / equity | 1.97 | 0.71 |
| Current ratio | 1.53 | 1.25 |
| Altman Z (solvency) | 2.25 | 1.88 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.